Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Kathleen Kemmer"'
Autor:
Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura J. van ‘t Veer, Douglas Yee, Stacy L. Moulder, Anne M. Wallace, A. Jo Chien, Claudine Isaacs, Judy C. Boughey, Kathy S. Albain, Kathleen Kemmer, Barbara B. Haley, Hyo S. Han, Andres Forero-Torres, Anthony Elias, Julie E. Lang, Erin D. Ellis, Rachel Yung, Debu Tripathy, Rita Nanda, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Rosa I. Gallagher, Teresa Helsten, Erin Roesch, Cheryl A. Ewing, Michael Alvarado, Erin P. Crane, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Nola M. Hylton, Donald A. Berry, Laura J. Esserman, Angela M. DeMichele
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
HER2-targeted therapy improves patient’s outcome in early breast cancer. Here, the authors present the efficacy and biomarker analysis of two HER2-targeted combinations (ado-trastuzumab emtansine plus pertuzumab and paclitaxel, trastuzumab and pert
Externí odkaz:
https://doaj.org/article/e6340916dac6476fac8b24ed5afd32c1
Autor:
Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Kathleen Kemmer, Rachel L. Yung, Paula R. Pohlmann, Debu Tripathy, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Emanuel F. Petricoin, Erica Stringer-Reasor, Carla I. Falkson, Melanie Majure, Rita A. Mukhtar, Teresa L. Helsten, Stacy L. Moulder, Patricia A. Robinson, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Nola M. Hylton, Angela DeMichele, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van‘t Veer, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a mono
Externí odkaz:
https://doaj.org/article/784de0fabd374658a9d09088fa4a5ee8
Autor:
Denise M. Wolf, Jane Perlmutter, Judy C. Boughey, A. Jo Chien, Meredith Buxton, Gillian L. Hirst, Douglas Yee, Angela DeMichele, Andres Forero-Torres, Scott M. Berry, Erin D. Ellis, Anthony D. Elias, Julia Wulfkuhle, Michael Alvarado, Christina Yau, Stacy L. Moulder, Nola M. Hylton, Rita Nanda, Amy Wilson, Adam Asare, Debu Tripathy, Claudine Isaacs, Melissa Paoloni, Rosa I. Gallagher, Laura J. Esserman, Richard Schwab, W. Fraser Symmans, Cheryl Ewing, Laura J. van't Veer, Jeffrey B. Matthews, Teresa Helsten, Julia L. Clennell, Barbara Haley, Emanuel F. Petricoin, Katherine Steeg, Smita Asare, Ashish Sanil, Rachel L. Yung, Erin P. Crane, Erin Roesch, Hyo S. Han, Ruby Singhrao, Michelle E. Melisko, Hope S. Rugo, Kathy S. Albain, Donald A. Berry, Anne M. Wallace, Julie E. Lang, Amy S. Clark, Kathleen Kemmer, Lamorna Brown-Swigart
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Nature communications, vol 12, iss 1
Nature Communications
Nature communications, vol 12, iss 1
Nature Communications
HER2-targeted therapy dramatically improves outcomes in early breast cancer. Here we report the results of two HER2-targeted combinations in the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast cancer at high risk of recurrence: ad
Autor:
Christina Yau, Marie Osdoit, Marieke van der Noordaa, Sonal Shad, Jane Wei, Diane de Croze, Anne-Sophie Hamy, Marick Laé, Fabien Reyal, Gabe S Sonke, Tessa G Steenbruggen, Maartje van Seijen, Jelle Wesseling, Miguel Martín, Maria del Monte-Millán, Sara López-Tarruella, Judy C Boughey, Matthew P Goetz, Tanya Hoskin, Rebekah Gould, Vicente Valero, Stephen B Edge, Jean E Abraham, John M S Bartlett, Carlos Caldas, Janet Dunn, Helena Earl, Larry Hayward, Louise Hiller, Elena Provenzano, Stephen-John Sammut, Jeremy S Thomas, David Cameron, Ashley Graham, Peter Hall, Lorna Mackintosh, Fang Fan, Andrew K Godwin, Kelsey Schwensen, Priyanka Sharma, Angela M DeMichele, Kimberly Cole, Lajos Pusztai, Mi-Ok Kim, Laura J van 't Veer, Laura J Esserman, W Fraser Symmans, Kathi Adamson, Kathy S. Albain, Adam L. Asare, Smita M. Asare, Ron Balassanian, Heather Beckwith, Scott M. Berry, Donald A. Berry, Judy C. Boughey, Meredith B. Buxton, Yunn-Yi Chen, Beiyun Chen, A. Jo Chien, Stephen Y. Chui, Amy S. Clark, Julia L. Clennell, Brian Datnow, Angela M. DeMichele, Xiuzhen Duan, Kirsten K. Edmiston, Anthony D. Elias, Erin D. Ellis, Laura L. Esserman, David M. Euhus, Oluwole Fadare, Michael D Feldman, Andres Forero-Torres, Barbara B. Haley, Hyo S. Han, Shuko Harada, Patricia Haugen, Teresa Helsten, Gillian L. Hirst, Nola M. Hylton, Claudine Isaacs, Kathleen Kemmer, Qamar J. Khan, Laila Khazai, Molly E. Klein, Gregor Krings, Julie E. Lang, Lauren G. LeBeau, Brian Leyland-Jones, Minetta C. Liu, Shelly Lo, Janice Lu, Anthony Magliocco, Jeffrey B. Matthews, Michelle E. Melisko, Paulette Mhawech-Fauceglia, Stacy L. Moulder, Rashmi K. Murthy, Rita Nanda, Donald W. Northfelt, Idris T. Ocal, Olufunmilayo Olopade, Stefan Pambuccian, Melissa Paoloni, John W. Park, Barbara A. Parker, Jane Perlmutter, Garry Peterson, Mara Rendi, Hope S. Rugo, Sunati Sahoo, Sharon Sams, Ashish Sanil, Husain Sattar, Richard B. Schwab, Ruby Singhrao, Katherine Steeg, Erica Stringer-Reasor, W. Fraser Symmans, Ossama Tawfik, Debasish Tripathy, Megan L. Troxell, Laura J. van't Veer, Sara J. Venters, Tuyethoa Vinh, Rebecca K. Viscusi, Anne M. Wallace, Shi Wei, Amy Wilson, Douglas Yee, Jay C. Zeck
Publikováno v:
I-SPY 2 Trial Consortium 2022, ' Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer : a multicentre pooled analysis of 5161 patients ', The Lancet Oncology, vol. 23, no. 1, pp. 149-160 . https://doi.org/10.1016/S1470-2045(21)00589-1
The Lancet. Oncology, vol 23, iss 1
The Lancet Oncology, 23(1), 149-160. Lancet Publishing Group
The Lancet. Oncology, vol 23, iss 1
The Lancet Oncology, 23(1), 149-160. Lancet Publishing Group
Background: Previous studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate the rel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9b5a03d8d05046179f5dcc364471bd0
https://research.vumc.nl/en/publications/4b35d135-33e6-4bf5-982e-dab0f5ddbfd8
https://research.vumc.nl/en/publications/4b35d135-33e6-4bf5-982e-dab0f5ddbfd8
Autor:
Ruby Singhrao, Jane Perlmutter, Angela DeMichele, A. Jo Chien, Christina Yau, HS Han, Donald A. Berry, Patricia A. Robinson, W. Fraser Symmans, Kevin Kalinsky, Laura J. Esserman, Richard Schwab, Anne M. Wallace, Erica Stringer-Reasor, Kathy S. Albain, Patricia K Haugen, Tara Sanft, Amy S. Clark, Ashish Sanil, Smita Asare, Laura J. van't Veer, Kathleen Kemmer, Hope S. Rugo, Amy Wilson, Janice Lu, Julie E. Lang, Minetta C. Liu, Anthony D. Elias, Nola M. Hylton, Rita Nanda, Claudine Isaacs, Douglas Yee, Michelle E. Melisko, Judy C. Boughey
Publikováno v:
Cancer Research. 80:P3-09
Background: I-SPY2 is a multicenter, response-adaptive randomization phase 2 trial to evaluate novel agents when added to standard neoadjuvant therapy for women with high-risk stage II/III breast cancer - weekly paclitaxel + investigational treatment
Autor:
Paul Haluska, Melanie Catherine Majure, Denise M. Wolf, Rachel L. Yung, Paula R. Pohlmann, Hyo S. Han, Jeffrey B. Matthews, Michelle E. Melisko, A. Jo Chien, Andres Forero-Torres, Kristen K. Edmiston, Adam Asare, Hope S. Rugo, Laura J. van't Veer, Jane Perlmutter, Debu Tripathy, Gillian L. Hirst, Anne M. Wallace, Patricia A. Robinson, Rita A. Mukhtar, Julia L. Clennell, W. Fraser Symmans, Judy C. Boughey, Scott M. Berry, Douglas Yee, Rita Nanda, Claudine Isaacs, Anthony D. Elias, Christina Yau, Julia Wulfkuhle, Nola M. Hylton, Emanuel F. Petricoin, Karthik V. Giridhar, Ashish Sanil, Smita Asare, Barbara Haley, Lajos Pusztai, Heather Beckwith, Laura J. Esserman, Kathleen Kemmer, Erin D. Ellis, Lamorna Brown-Swigart, Meredith Buxton, Stacy L. Moulder, Melissa Paoloni, Teresa Helsten, Donald A. Berry, Carla I. Falkson, Kathy S. Albain, Amy S. Clark, Angela DeMichele, Erica Stringer-Reasor, Qamar J. Khan, Amy Wilson, Ruby Singhrao
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
NPJ breast cancer, vol 7, iss 1
NPJ Breast Cancer
NPJ breast cancer, vol 7, iss 1
NPJ Breast Cancer
I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a monoclonal an
Autor:
Shi Wei, Richard Schwab, Gregor Krings, Lajos Pusztai, Rashmi Krishna Murthy, Lauren LeBeau, Megan L. Troxell, Adam Asare, Erin D. Ellis, Sharon Sams, Donald A. Berry, Fang Fan, Anne M. Wallace, Andres Forero-Torres, Christina Yau, Angela DeMichele, Donald W. Northfelt, Mara H. Rendi, Laila Khazai, Husain Sattar, Xiuzhen Duan, Ronald Balassanian, Rebecca K. Viscusi, Hyo S. Han, Barbara A. Parker, A. Jo Chien, Brian Leyland-Jones, Meredith Buxton, Idris Tolgay Ocal, Yunn Yi Chen, Qamar J. Khan, Brian Datnow, Barbara Haley, Tuyethoa Vinh, Kathy S. Albain, Laura van 't Veer, Minetta C. Liu, Michael Feldman, Amy S. Clark, Kirsten H. Edmiston, W. Fraser Symmans, Sonal Shad, Kathleen Kemmer, Judy C. Boughey, Julie E. Lang, Paulette Mhawech-Fauceglia, Teresa Helsten, Douglas Yee, Molly Klein, Rita Nanda, Claudine Isaacs, Anthony D. Elias, Sara J. Venters, Nola M. Hylton, Jay Zeck, Laura J. Esserman, Beiyun Chen, Hope S. Rugo, Smita Asare, Sunati Sahoo, Jeffrey B. Matthews, Jane Perlmutter
Publikováno v:
JAMA Oncol
Importance Residual cancer burden (RCB) distributions may improve the interpretation of efficacy in neoadjuvant breast cancer trials. Objective To compare RCB distributions between randomized control and investigational treatments within subtypes of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::970e2b28a3f16ef394eea6cc208edc54
https://europepmc.org/articles/PMC8446908/
https://europepmc.org/articles/PMC8446908/
Autor:
Kathleen Kemmer, Nicole Roy, Alina Tudorica, May Mishal, Wei Huang, Eric Goranson, Megan L. Troxell, Megan L. Holtorf, Karen Y. Oh, Arpana Naik, Archana Machireddy, Neda Jafarian, Guillaume Thibault, Xubo Song, Aneela Afzal
Publikováno v:
Tomography
Volume 5
Issue 1
Pages 90-98
Tomography; Volume 5; Issue 1; Pages: 90-98
Volume 5
Issue 1
Pages 90-98
Tomography; Volume 5; Issue 1; Pages: 90-98
We aimed to determine whether multiresolution fractal analysis of voxel-based dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parametric maps can provide early prediction of breast cancer response to neoadjuvant chemotherapy (NACT). In
Autor:
Debu Tripathy, AS Clark, AD Elias, William Fraser Symmans, Je Lang, Amy Wilson, Kirsten H. Edmiston, Christos Vaklavas, Preya Shah, L.J. van 't Veer, Melanie Catherine Majure, Denise M. Wolf, Judy C. Boughey, Amy Jo Chien, M. Melisko, Nola M. Hylton, Richard Schwab, Christina Yau, Rita Nanda, Claudine Isaacs, Barbara Haley, Teresa Helsten, Donald A. Berry, HS Han, Erin D. Ellis, Erica Stringer-Reasor, Qamar J. Khan, KS Albain, Nora Jaskowiak, Erin Roesch, S Asare, AM DeMichele, HS Rugo, Cheryl Ewing, LJ Esserman, C Lee, Tufia C. Haddad, Kathleen Kemmer, Larissa A. Korde, Anne M. Wallace, Jane Perlmutter, Ruby Singhrao, D Yee, Andres Forero, Rebecca K. Viscusi, Janice Lu, Donald W. Northfelt
Publikováno v:
Cancer Research. 79:P1-15
This abstract was withdrawn by the authors. Citation Format: Schwab R, Clark A, Yau C, Wolf D, Chien AJ, Majure M, Ewing C, Wallace A, Roesch E, Helsten T, Forero A, Stringer-Reasor E, Vaklavas C, Nanda R, Jaskowiak N, Boughey J, Haddad T, Han H, Lee
Autor:
Erin D. Ellis, Shelly S. Lo, William C. Wood, C Isaacs, L Korde, Kirsten K. Edmiston, Debu Tripathy, D Yee, Je Lang, Sy Chui, MC Liu, Heather Beckwith, Rita Nanda, DW Northfelt, Kathleen Kemmer, E Price, Judy C. Boughey, L Pusztai, AS Clark, A Forero-Torres, Rita A. Mukhtar, John W. Park, KS Albain, AJ Chien, L Suleiman, HS Han, Richard Schwab, O. I. Olopade, C Yau, S. L. Moulder, R Singhrao, DM Euhus, A DeMichele, S Asare, Rebecca K. Viscusi, Donald A. Berry, Anne M. Wallace, J Lu, HS Rugo, AD Elias, J Silverstein, LJ Esserman, Teresa Helsten, QJ Khan, Brian Leyland-Jones
Publikováno v:
Cancer Research. 79:P2-14
Background: In women with breast cancer receiving neoadjuvant chemotherapy, residual cancer burden (RCB) predicts distant recurrence and survival. In those with high risk tumors, locoregional recurrence (LRR) remains a concern, and has been associate